{
    "nct_id": "NCT06635824",
    "official_title": "A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)",
    "inclusion_criteria": "* Participant has histologically or cytologically confirmed metastatic NSCLC (stage IV).\n* Participant has progressed on or after receiving:\n\n  * One prior line of therapy (PD-1/PD-L1 inhibitor and platinum-based chemotherapy concomitantly) in the metastatic disease setting; OR\n  * No more than 2 prior lines of therapy (PD-1/PD-L1 inhibitor and platinum-based chemotherapy sequentially, irrespective of the order) in the metastatic disease setting.\n* Participant must have positive tumor PD-L1 expression (tumor cells ≥1%) determined prospectively on a tumor sample from the metastatic setting at a sponsor-designated central laboratory.\n* Participant has measurable disease according to RECIST v1.1 as assessed by the investigator at baseline.\n* Participant has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 within 7 days of Cycle 1 Day 1.\n* Participant has a life expectancy of ≥3 months.\n* Participant must have adequate organ and bone marrow function, per laboratory test results within 7 days of trial treatment.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Documentation of known targetable epidermal growth factor receptor (EGFR) sensitizing mutations, anaplastic lymphoma kinase (ALK), RET proto-oncogene (RET), ROS proto-oncogene 1; receptor tyrosine kinase (ROS1) rearrangement, Kirsten rat sarcoma virus (KRAS), BRAF mutations, and MET exon 14 skipping mutations/MET amplification. NOTE: MET amplification testing is optional based on local availability of the test.\n\n  * Participants with known KRAS/BRAF mutations are eligible for the trial if they do not have access to approved targeted therapies.\n* Participants with newly identified or known unstable or symptomatic central nervous system (CNS) metastases or history of carcinomatous meningitis.\n* Prior treatment with docetaxel for NSCLC.\n* Prior treatment with a 4-1BB (CD137) targeted agent, any type of antitumor vaccine, autologous cell immunotherapy, or any unapproved immunotherapy.\n* Treatment with an anticancer agent within 28 days prior to the first dose of trial treatment.\n\nNote: Other protocol-defined inclusion and exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}